The antibiotics marketplace collapse: It’s just math and it’s a solvable equation

There is a growing awareness that companies with newly approved antibiotics face substantial economic challenges. Yet we remain concerned that there is a general lack of understanding of the mechanics driving the collapse of the industry. Understanding the root causes and identifying which are addressable through alternate strategies or changes in behaviors vs. those that are a fundamental feature of the antibacterial marketplace is critical to finding lasting solutions.

Diagnostics to safeguard new and current antibiotics for gonorrhoea

Gonorrhoea and chlamydia are the two most common sexually transmitted infections in the world. Their similar symptoms make it challenging to differentiate between the infections and treat appropriately. As a consequence, syndromic treatment of gonorrhoea leads to inappropriate use of antibiotics. Cassandra Kelly-Cirino and Cecilia Ferreyra from FIND discuss why new and better diagnostics are needed to safeguard drugs to treat gonorrhoea.

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.